Serum Institute sets out for dengue fast track

Serum CEO Adar Poonawalla

Asia's largest vaccinemaker just made a play that could affect the race for a vaccine protecting against dengue fever, a common affliction that has a big impact in the region.

The Serum Institute of India announced on Tuesday that it's seeking fast-track approval to launch a dengue treatment in India for which it purchased local rights from U.S. biotech Visterra earlier this month. If successful, the company could be the first globally to launch a drug for the mosquito-borne illness, Reuters reports--a development with potential implications in the ongoing dengue vaccine race between Sanofi, Takeda, and others.

Serum CEO Adar Poonawalla told the news service his company will seek approval in a year to a year and a half versus the three to four years typically required for vaccines. However, Sanofi ($SNY), which has spent 20 years and $1.5 billion developing its vaccine, plans to launch yet this year in the region: Its vaccines head, Olivier Charmeil, said the company will have filed for approval in 20 countries--representing approximately half of the world's population at risk of dengue--by the end of this year.

Serum's play comes amid the worst dengue outbreak in 5 years in India's capital, New Delhi, which has caused high death rates and showcased the area's inadequate measures against the disease.

The news capped a busy day for the vaccinemaker, which also announced on Tuesday that it will halt a planned stake sale amid fears of a global slowdown, India's Business Standard reported. The company, fully owned by the Poonawalla family, previously planned to divest a 10% stake of a desired $12 billion valuation.

For its dengue vaccine launch, Sanofi has said it's "flipping the model," placing its focus on dengue-stricken nations and favoring wide uptake. Despite that company's progress, analysts have predicted Takeda could be battling for market share with DENVax by 2020. Merck ($MRK) and GlaxoSmithKline ($GSK) are further off with their candidates.

- here's the Reuters story
- read more from Business Standard
- get FiercePharmaAsia's take

Related Articles:
Two dengue treatments slated for PhII in Singapore next year
Sanofi's dengue vaccine anticipated on profitability 'high end'
Singapore clinical hub to work with Visterra on dengue candidate
Sanofi Pasteur U.S. operation part of dengue vaccine buildup
Sanofi 'flipping the model' for high-stakes dengue rollout
Sanofi, armed with more strong PhIII dengue data, sets sights on 2015 rollout
Report: Takeda's dengue jab will be nipping at Sanofi's heels by 2020